Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.765 USD | +0.28% | +7.32% | +15.03% |
Sales 2024 * | 24.2M 33.16M | Sales 2025 * | 83.79M 115M | Capitalization | 636M 872M |
---|---|---|---|---|---|
Net income 2024 * | -200M -274M | Net income 2025 * | -201M -275M | EV / Sales 2024 * | 26.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.59 x |
P/E ratio 2024 * |
-2.3
x | P/E ratio 2025 * |
-2.57
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 day | +0.28% | ||
1 week | +7.32% | ||
Current month | +3.53% | ||
1 month | -3.83% | ||
3 months | -21.78% | ||
6 months | +54.39% | ||
Current year | +15.03% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +8.96% | - | |
0.00% | 1,487 M€ | +7.64% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 1.76 | 0.00% | 297 240 |
24-06-04 | 1.76 | +0.57% | 1,740,387 |
24-06-03 | 1.75 | +2.94% | 2,343,281 |
24-05-31 | 1.7 | 0.00% | 1,760,801 |
24-05-30 | 1.7 | +3.66% | 1,058,986 |
Delayed Quote Nasdaq, June 05, 2024 at 09:58 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.03% | 636M | |
+17.08% | 123B | |
+13.29% | 107B | |
-6.10% | 24.01B | |
+2.01% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-12.25% | 16.23B | |
+1.81% | 13.43B | |
+22.48% | 11.32B |
- Stock Market
- Equities
- LXRX Stock